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Tab. 1: Results, 2014 
Sensitivity Analysis
In the deterministic one-way sensitivity analyses (Figure 2 ), our results were robust to a wide range of plausible estimates of unit cost data. Cost savings persisted for the new-born screening strategy in all variations of the sensitivity analyses. Costs for moderate development delay and the NBS costs exhibit the great influence on total costs . Variation of the NBS costs are associated with a rang of costs (16,1€-24,12€) per child in the NBS arm. The incremental cost-effectiveness advantage for the screening strategy ranged between -1.653,13€ to 2.039,80€.
Clinical Data
Incidence rates of each disease were derived from the nationwide database of the reference center (Medical University of Vienna) and included data over 10 years. Probabilities of sequelae, mortality rates and quality adjusted survival rates were derived from the literature.
Resource Use and Costs
Resource use and cost of screening were derived from the nationwide database of the reference center. Data on the resource use of the included diseases and sequelae were collected in two steps. First, the medical resources were derived by literature (e.g. disease specific guidelines). In a second step this literature review was verified by experts. Direct medical costs derived from a number of publicly available sources like outpatient clinic catalogue as well as the DRG catalogue (LKF) and official price lists for the Austrian Health insurances funds. Indirect Cost represent statistical and published data as well as own calculations. When necessary, prices were adjusted to 2014 prices using the consumer price index. 
Methods
We developed a decision-analytic model, which include specific Markov processes for the core disorders: cystic fibrosis (CF), phenylketonuria (PKU), medium-chain acyl-CoA (MCAD), congenital hypothyroidism (CH), galactosemia (GAL) and maple syrup urine disease (MSUD). Costs and health benefits were estimated for a cohort of new-borns in Austria (77,761 births per year). The analysis focused on lifetime consequences. This encompassed direct costs (including screening costs and cost of illness), quality-adjustedlife-years (QALYs) and reduced expectation of life. Costs were presented per child and for the Austrian birth cohort. Costs from published sources were used (2014 Euro) from the health care systems perspective. QALYs, life-years (LYs) and costs were projected over a life-time horizon and discounted at 3% per year.
Source: IPF own developed Transferred to the entire birth cohort, new-born screening is able to reduce total costs of 14.07 million € from the Austrian health care systems perspective each year. Screening results in 6,744 QALYs gained and more than 5,482 LYs saved for the entire birth cohort.
Markov subtree cystic fibrosis
Markov subtree phenylketonuria [+] [+] Decision model [+] indicates that the subtree is not completely displayed. The content of the subtrees are the same as in the subtree above.
MCAD, CH, GAL and MSUD subtree not displayed MS/MS testing costs amounts 20.07 Euro.
Tests marked as "Dominates" save money and improve outcome relative to no testing. Table 1 demonstrates that the total panel is able to save money and improve outcome.
